Fresh Zealand’s ADHD Medication Crisis: A Looming Health Challenge
A critical shortage of ADHD medication in New Zealand is escalating, with Pharmac, the country’s drug-buying agency, acknowledging it as its “most significant supply issue.” The shortfall, impacting medications like Concerta (18mg, 27mg) and Teva (36mg), is projected to persist throughout 2026, raising concerns about patient wellbeing and access to essential treatment.
The Growing Demand and Supply Chain Vulnerabilities
The number of New Zealanders diagnosed with ADHD and prescribed long-acting methylphenidate medications has surged, increasing from 49,000 in 2023 to 69,000 in 2025. This dramatic rise in demand is colliding with global supply chain disruptions, leaving Pharmac struggling to secure adequate supplies. The situation isn’t unique to New Zealand; it’s an international problem, highlighting reliance on overseas pharmaceutical companies.
Patient Experiences and Potential Risks
The impact on patients is significant. Lizzie Sayegh, an ADHD patient, described the situation as an “ADHD apocalypse,” detailing a six-month period of switching between four different medications due to limited access to Concerta. This disruption led to cognitive difficulties and sleep disturbances. Experts warn that inconsistent medication access can lead to increased rates of non-accident injuries and suicide in individuals with ADHD.
Expanding Access to Diagnosis and Treatment
Recent changes allowing GPs and nurse practitioners to diagnose and prescribe ADHD medication, implemented in early 2026, were initially delayed due to supply concerns. While intended to broaden access to care, the increased demand further strains the already limited medication supply. Pharmac has responded by funding additional brands of methylphenidate (Sandoz) and considering funding another (Rubifen LA), as well as lisdexamfetamine (Vyvanse) to provide more treatment options.
The Role of Methylphenidate and OROS Delivery System
Concerta utilizes a unique OROS (osmotically controlled release oral-delivery system) designed to release methylphenidate gradually throughout the day. Methylphenidate is also the active ingredient in other ADHD medications like Ritalin. Yet, individuals may respond differently to various brands, experiencing variations in duration of effect and side effects. Finding the right medication and consistent access are crucial for effective symptom management.
Looking Ahead: Potential Solutions and Future Trends
Addressing this crisis requires a multi-faceted approach. Diversifying medication sources, strengthening supply chain resilience, and investing in research into alternative treatments are essential. Increased funding for ADHD awareness and diagnosis could also help manage demand by ensuring appropriate medication use. The development of long-acting, non-stimulant medications could offer additional options for patients who don’t respond well to stimulants or experience intolerable side effects.
FAQ: ADHD Medication Shortages in New Zealand
Q: What medications are currently affected by the shortage?
A: Currently, 18mg and 27mg Concerta, and 36mg Teva are out of stock.
Q: When are shipments expected?
A: Teva shipments are due in February 2026, while Concerta shipments are estimated to arrive at the end of March 2026.
Q: What is Pharmac doing to address the shortage?
A: Pharmac is working with suppliers, funding new brands of methylphenidate (Sandoz), and considering funding additional options (Rubifen LA) and lisdexamfetamine (Vyvanse).
Q: What is the OROS delivery system?
A: OROS is a unique system used in Concerta that allows for a gradual release of medication throughout the day.
Q: Could the changes allowing GPs to prescribe ADHD medication worsen the shortage?
A: The increased demand resulting from broader prescribing access could potentially exacerbate the existing supply issues.
Did you know? ADHD is a neurodevelopmental condition affecting approximately 5% of children and 2.5% of adults.
Pro Tip: If you are experiencing difficulties accessing your ADHD medication, discuss alternative options with your healthcare provider.
Stay informed about the latest updates on ADHD medication availability and treatment options. Share your experiences and connect with others in the ADHD community to advocate for improved access to care.